BioSyent Inc. (CVE:RX - Get Free Report)'s share price crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of C$11.06 and traded as low as C$10.76. BioSyent shares last traded at C$10.76, with a volume of 1,412 shares.
BioSyent Stock Up 3.7 %
The business's 50 day moving average is C$11.04 and its 200 day moving average is C$11.10. The stock has a market cap of C$128.10 million, a price-to-earnings ratio of 18.18 and a beta of 0.93. The company has a debt-to-equity ratio of 2.90, a quick ratio of 6.91 and a current ratio of 3.92.
Insider Buying and Selling at BioSyent
In other BioSyent news, insider FAX Capital Corp. sold 112,400 shares of BioSyent stock in a transaction on Monday, December 23rd. The shares were sold at an average price of C$11.28, for a total transaction of C$1,267,557.28. Company insiders own 33.65% of the company's stock.
About BioSyent
(
Get Free Report)
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
Further Reading
Before you consider BioSyent, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioSyent wasn't on the list.
While BioSyent currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
